Skip Navigation


NDT Plus Advance Access originally published online on April 5, 2008
NDT Plus 2008 1(4):241-243; doi:10.1093/ndtplus/sfn027
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/4/241    most recent
sfn027v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shores, N. J.
Right arrow Articles by Kimberly, J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Seronegative hepatitis C-related fibrosing cholestatic hepatitis after renal transplant: a case report and review of the literature

Nathan J. Shores and James Kimberly

Section of Gastroenterology, Department of Internal Medicine, Wake Forest University Health System, Winston-Salem, NC, USA

Correspondence: Nathan J. Shores, Section of Gastroenterology, Department of Internal Medicine, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel: +1-336-716-1114; Fax: +1-336-713-7312; E-mail: NShores{at}wfubmc.edu

Key Words: cholestasis • cirrhosis • hepatic fibrosis • hepatitis C • renal transplant

Received for publication January 30, 2008. Accepted for publication February 21, 2008.


   Case
Top
 Case
Discussion
 References
 
Ms J is a 52-year-old female who underwent deceased donor renal transplant (RT) in May 2006 for membranous glomerulonephritis after 6 years on haemodialysis. She was initially treated post-transplant with alemtuzumab (Campath) secondary to delayed graft function and was subsequently discharged on tacrolimus, mycophenolate and prednisone for chronic immunosuppression. Ms J tested negative for anti-HCV in her first transplant consultation in 2004 and again just 12 days prior to surgery. Her bilirubin (0.5 mg/dL), alkaline phosphatase (ALP 94 IU/L), aspartate aminotransferase (AST 28 IU/L) and alanine aminotransferase (ALT 14 IU/L) were all within normal limits before transplant.

Subsequently, Ms J's alkaline phosphatase rose to 178 IU/L 7 days after procedure. Within 6 months her aminotransferases (AST 96 IU/L and ALT 78 IU/L) and bilirubin (1.5 mg/dL) became elevated as well, never returning normal. At that time tacrolimus was stopped in favor of cyclosporine, and computed tomography (CT) of the abdomen demonstrated cholelithiasis and small ascites. Despite this, an elective laparoscopic cholecystectomy did not result in improved liver chemistries and several repeat measurements of chronic anti-HCV/HBV antibody serologies remained negative. Testing for abnormal anti-nuclear antibodies (ANA), anti-smooth muscle antibody (ASMA), anti-mitochondial antibody (AMA) and quantitative immunoglobulins was also negative. Unfortunately, HCV RNA testing was not done. Over the next 7 months, Ms J became increasingly jaundiced with worsening, symptomatic ascites. This corresponded with declining renal graft function and uraemia.

A gastroenterology consult led to a transjugular liver biopsy 13 months after RT indicated cholestasis, periportal fibrosis and acute inflammation of the bile ducts with associated regeneration, and only mild lobular inflammation (figure 1). Features of HCV hepatitis were absent. A repeated anti-HCV assay at that time was negative, but HCV RNA by B-DNA was positive for 7.69 x 106 eq/mL of genotype 1a virus. Ms J was diagnosed with FCH C cirrhosis with renal allograft dysfunction from acute tubular necrosis and chronic rejection. She was felt to be unsuitable for HCV therapy and is currently exploring combined liver and RT.


Figure 1
View larger version (145K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Liver biopsy 13 months post-renal transplant. Acute cholangioliotis with neutrophil infiltration, hepatocyte ballooning (arrow) and disruption of the bile ductule (dashed arrows).

 

   Discussion
Top
 Case
 Discussion
References
 
Only 14 cases of FCH in RT recipients secondary to HCV infection have been previously described. Prior to Zyldeberg et al.'s original report in 1995, FCH was an ominous complication of immunosuppressed liver transplant recipients infected with HBV and—less often—HCV [1–5]. Several other reports confirmed that a small subset of HCV-infected RT patients develop a rapidly progressive FCH, characterized by acute cholangiolitis, hepatocellular swelling and mild periportal fibrosis rather than the acidophilic hepatocyte necrosis, lobular inflammation or pericellular/sinusoidal fibrosis associated with HCV hepatitis [1,6–10].

Munoz et al. was the next to report FCH as a rare, but serious, complication in a cohort of known HCV-infected patients (4 out 259) status post-renal transplantation [11]. Like Ms J, these four patients were predominantly genotype 1, lacked the typical features of HCV hepatitis and had a rapid progression to severe liver dysfunction and/ordeath (Table 1). In Delladetsima et al.'s subsequent report of FCH in four seronegative HCV-infected RT recipients—despite abrupt immunosupression reduction in all four patients—only two patients seroconverted and had rapid improvement of their liver disease [7]. Similar to Ms J, three of the four patients were genotype 1, and all were on methylprednisone, azothiporine and cyclosporine A. Also like Ms J, two persistently anti-HCV negative patients suffered progressively worsening liver function and end-stage liver disease within 18 months of RT. The authors propose this phenomenon may be secondary to peri-operative infection and aggressive post-transplant immunosupression.


View this table:
[in this window]
[in a new window]

  		Table 1 Clinical characteristics of patients diagnosed with HCV-related FCH after RT

 
A follow-up retrospective analysis by the same group sought to clarify the effect that the timing of HCV infection had on the development of FCH in 17 RT recipients who were seronegative at the time of transplant, but who developed HCV RNA positive disease after surgery [6]. As in our case, this study observed a short mean time to new biochemical abnormalities in liver function (5.7 months) in the four patients diagnosed with FCH. Also, three patients with FCH at the time of the first biopsy (including the two who never seroconverted) were on triple immunosuppression and infected with HCV genotype 1. Finally, two persistently anti-HCV negative patients faired poorly, dying with advanced liver disease in a median of 6 years.

The factors influencing this rare complication remain unclear. Further study is indicated to determine if the FCH pattern of liver damage in RT patients is related to the timing of infection, aggressive early immunosuppression, patient-specific properties of immunity or HCV genotype as our case and previous reports suggest. Additionally, this case highlights the role of HCV RNA for screening in an immunosupressed population. While the false negative rate of anti-HCV testing for chronic HCV in high prevalence populations is 5%, multiple studies indicate a failure to form measured antibodies in up to 15% of haemodialysis and transplant patients [12–16]. Unfortunately, it was too long presumed that anti-HCV antibody alone was an adequate diagnostic tool in this case. Like Ms J, RT candidates would benefit from early HCV RNA testing for pre-surgical screening or to diagnose post-RT liver abnormalities. Finally, reversal of clinical liver disease in these patients has been reported with the discontinuation of immunosupression or the use of PEG interferon, but obviously the experience is limited [17]. A prospective trial is needed to confirm if pre- or post-transplant anti-HCV therapy will positively affect transplant outcomes.


   Acknowledgements
 
Thanks is due to Dr. Emmett B. Keeffe, MD of Stanford University, USA for his assistance reviewing this work before publication.

Conflict of interest statement. None declared.


   References
Top
 Case
 Discussion
 References
 

  1. Zylberberg H, Carnot F, Mamzer MF, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation (1997) 63:158–160.[CrossRef][Web of Science][Medline]
  2. Davies SE, Portmann BC, O’Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology (1991) 13:150–157.[CrossRef][Web of Science][Medline]
  3. Booth JC, Goldin RD, Brown JL, et al. Fibrosing cholestatic hepatitis in a renal transplant recipient associated with the hepatitis B virus precore mutant. J Hepatol (1995) 22:500–503.[CrossRef][Web of Science][Medline]
  4. Chen CH, Chen PJ, Chu JS, et al. Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology (1994) 107:1514–1518.[Medline]
  5. Hung YB, Liang JT, Chu JS, et al. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. Hepatogastroenterology (1995) 42:913–918.[Medline]
  6. Delladetsima I, Psichogiou M, Sypsa V, et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis (2006) 47:309–316.[CrossRef][Web of Science][Medline]
  7. Delladetsima JK, Boletis JN, Makris F, et al. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg (1999) 5:294–300.[CrossRef][Web of Science][Medline]
  8. Delladetsima JK, Makris F, Psichogiou M, et al. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection. Liver (2001) 21:81–88.[CrossRef][Web of Science][Medline]
  9. Hooda AK, Puri P, Narula AS, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis in a renal transplant recipient. Indian J Gastroenterol (2006) 25:308–309.[Medline]
  10. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl (2007) 13:219–226.[CrossRef][Web of Science][Medline]
  11. Munoz De Bustillo E, Ibarrola C, Colina F, et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol (1998) 9:1109–1113.[Abstract]
  12. Dalekos GN, Boumba DS, Katopodis K, et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant (1998) 13:1804–1806.[Abstract/Free Full Text]
  13. Lok AS, Chien D, Choo QL, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology (1993) 18:497–502.[CrossRef][Web of Science][Medline]
  14. Chan TM, Lok AS, Cheng IK, et al. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology (1993) 17:5–8.[Web of Science][Medline]
  15. Hadlich E, Alvares-Da-Silva MR, Dal Molin RK, et al. Hepatitis C virus (HCV) viremia in HIV-infected patients without HCV antibodies detectable by third-generation enzyme immunoassay. J Gastroenterol Hepatol (2007) 22:1506–1509.[CrossRef][Web of Science][Medline]
  16. Gretch DR. Diagnostic tests for hepatitis C. Hepatology (1997) 26(3 Suppl 1):S43–S47.[CrossRef][Web of Science]
  17. Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation (1998) 66:1254–1258.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/4/241    most recent
sfn027v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shores, N. J.
Right arrow Articles by Kimberly, J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?